Literature DB >> 23032747

Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation.

Johan Botling1, Karolina Edlund, Miriam Lohr, Birte Hellwig, Lars Holmberg, Mats Lambe, Anders Berglund, Simon Ekman, Michael Bergqvist, Fredrik Pontén, André König, Oswaldo Fernandes, Mats Karlsson, Gisela Helenius, Christina Karlsson, Jörg Rahnenführer, Jan G Hengstler, Patrick Micke.   

Abstract

PURPOSE: Global gene expression profiling has been widely used in lung cancer research to identify clinically relevant molecular subtypes as well as to predict prognosis and therapy response. So far, the value of these multigene signatures in clinical practice is unclear, and the biologic importance of individual genes is difficult to assess, as the published signatures virtually do not overlap. EXPERIMENTAL
DESIGN: Here, we describe a novel single institute cohort, including 196 non-small lung cancers (NSCLC) with clinical information and long-term follow-up. Gene expression array data were used as a training set to screen for single genes with prognostic impact. The top 450 probe sets identified using a univariate Cox regression model (significance level P < 0.01) were tested in a meta-analysis including five publicly available independent lung cancer cohorts (n = 860).
RESULTS: The meta-analysis revealed 14 genes that were significantly associated with survival (P < 0.001) with a false discovery rate <1%. The prognostic impact of one of these genes, the cell adhesion molecule 1 (CADM1), was confirmed by use of immunohistochemistry on tissue microarrays from 2 independent NSCLC cohorts, altogether including 617 NSCLC samples. Low CADM1 protein expression was significantly associated with shorter survival, with particular influence in the adenocarcinoma patient subgroup.
CONCLUSIONS: Using a novel NSCLC cohort together with a meta-analysis validation approach, we have identified a set of single genes with independent prognostic impact. One of these genes, CADM1, was further established as an immunohistochemical marker with a potential application in clinical diagnostics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23032747     DOI: 10.1158/1078-0432.CCR-12-1139

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  164 in total

1.  Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade.

Authors:  Bo Ryeong Lee; Sehyun Chae; Jihyun Moon; Myeong Joon Kim; Hankyu Lee; Hyuk Wan Ko; Byoung Chul Cho; Hyo Sup Shim; Daehee Hwang; Hye Ryun Kim; Sang-Jun Ha
Journal:  JCI Insight       Date:  2020-07-23

2.  Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma.

Authors:  Yulong Chen; Masahiko Terajima; Yanan Yang; Li Sun; Young-Ho Ahn; Daniela Pankova; Daniel S Puperi; Takeshi Watanabe; Min P Kim; Shanda H Blackmon; Jaime Rodriguez; Hui Liu; Carmen Behrens; Ignacio I Wistuba; Rosalba Minelli; Kenneth L Scott; Johannah Sanchez-Adams; Farshid Guilak; Debananda Pati; Nishan Thilaganathan; Alan R Burns; Chad J Creighton; Elisabeth D Martinez; Tomasz Zal; K Jane Grande-Allen; Mitsuo Yamauchi; Jonathan M Kurie
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

3.  A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.

Authors:  Lu Chen; Brienne E Engel; Eric A Welsh; Sean J Yoder; Stephen G Brantley; Dung-Tsa Chen; Amer A Beg; Chunxia Cao; Frederic J Kaye; Eric B Haura; Matthew B Schabath; W Douglas Cress
Journal:  J Thorac Oncol       Date:  2016-02-23       Impact factor: 15.609

4.  A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma.

Authors:  Ron Chen; Purvesh Khatri; Pawel K Mazur; Melanie Polin; Yanyan Zheng; Dedeepya Vaka; Chuong D Hoang; Joseph Shrager; Yue Xu; Silvestre Vicent; Atul J Butte; E Alejandro Sweet-Cordero
Journal:  Cancer Res       Date:  2014-03-20       Impact factor: 12.701

5.  ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.

Authors:  Yanan Yang; Young-Ho Ahn; Yulong Chen; Xiaochao Tan; Lixia Guo; Don L Gibbons; Christin Ungewiss; David H Peng; Xin Liu; Steven H Lin; Nishan Thilaganathan; Ignacio I Wistuba; Jaime Rodriguez-Canales; Georgia McLendon; Chad J Creighton; Jonathan M Kurie
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

6.  Integrative analyses of noncoding RNAs reveal the potential mechanisms augmenting tumor malignancy in lung adenocarcinoma.

Authors:  Jou-Ho Shih; Hsin-Yi Chen; Shin-Chih Lin; Yi-Chen Yeh; Roger Shen; Yaw-Dong Lang; Dung-Chi Wu; Chien-Yu Chen; Ruey-Hwa Chen; Teh-Ying Chou; Yuh-Shan Jou
Journal:  Nucleic Acids Res       Date:  2020-02-20       Impact factor: 16.971

7.  Rac3 regulates cell proliferation through cell cycle pathway and predicts prognosis in lung adenocarcinoma.

Authors:  Gebang Wang; Huan Wang; Chenlei Zhang; Tieqin Liu; Qingchang Li; Xuyong Lin; Jingwei Xie; Hongxu Liu
Journal:  Tumour Biol       Date:  2016-07-11

Review 8.  Integrating omics technologies to study pulmonary physiology and pathology at the systems level.

Authors:  Ravi Ramesh Pathak; Vrushank Davé
Journal:  Cell Physiol Biochem       Date:  2014-04-28

9.  Profiling cancer testis antigens in non-small-cell lung cancer.

Authors:  Dijana Djureinovic; Björn M Hallström; Masafumi Horie; Johanna Sofia Margareta Mattsson; Linnea La Fleur; Linn Fagerberg; Hans Brunnström; Cecilia Lindskog; Katrin Madjar; Jörg Rahnenführer; Simon Ekman; Elisabeth Ståhle; Hirsh Koyi; Eva Brandén; Karolina Edlund; Jan G Hengstler; Mats Lambe; Akira Saito; Johan Botling; Fredrik Pontén; Mathias Uhlén; Patrick Micke
Journal:  JCI Insight       Date:  2016-07-07

Review 10.  Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Authors:  Tim N Beck; Adaeze J Chikwem; Nehal R Solanki; Erica A Golemis
Journal:  Physiol Genomics       Date:  2014-08-05       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.